Isabelle Solomon is the R&D Site Manager at Nurexone, overseeing cutting-edge research initiatives aimed at advancing exosome-based therapies.
She is an experienced R&D scientist specializing in cancer immunotherapy, with a proven track record of guiding innovative projects from pre-clinical stages to clinical trials. Prior to joining Nurexone, Isabelle played a key role at Gamida Cell, where she was instrumental in advancing the company’s lead NK cell product, GDA-201, from pre-clinical stages to a successful Phase I clinical trial under FDA oversight.
This role underscored her ability to navigate complex regulatory landscapes while achieving critical development milestones. Dr. Solomon holds a PhD in Cancer Immunotherapy from University College London (UCL), where she focused on novel immunotherapeutic approaches to target cancer cells. She has successfully led international collaborations, developed robust analytical methods, and ensured regulatory compliance across academic and industry settings. Her technical expertise spans flow cytometry, molecular biology, and GMP standards, complemented by her strong skills in project management, scientific writing, and team leadership.